JP7303184B2 - 凍結保存細胞製剤および細胞再生方法 - Google Patents

凍結保存細胞製剤および細胞再生方法 Download PDF

Info

Publication number
JP7303184B2
JP7303184B2 JP2020515812A JP2020515812A JP7303184B2 JP 7303184 B2 JP7303184 B2 JP 7303184B2 JP 2020515812 A JP2020515812 A JP 2020515812A JP 2020515812 A JP2020515812 A JP 2020515812A JP 7303184 B2 JP7303184 B2 JP 7303184B2
Authority
JP
Japan
Prior art keywords
cells
cryopreserved
formulation
cell
cryopreservation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520680A5 (enExample
JP2020520680A (ja
Inventor
リ ヂャン
フェイ ワン
ジァピン ヘ
ナンジン リン
リピン リュウ
シン リュウ
チャオ リ
シュキエン ユ
ヨンライ フ
ジャウェイ ヂャオ
ヂェ スン
シャオユ リュウ
Original Assignee
セルラー バイオメディシン グループ （シャンハイ） リミテッド
セルラー バイオメディシン グループ （ウーシー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー バイオメディシン グループ （シャンハイ） リミテッド, セルラー バイオメディシン グループ （ウーシー） リミテッド filed Critical セルラー バイオメディシン グループ （シャンハイ） リミテッド
Publication of JP2020520680A publication Critical patent/JP2020520680A/ja
Publication of JP2020520680A5 publication Critical patent/JP2020520680A5/ja
Application granted granted Critical
Publication of JP7303184B2 publication Critical patent/JP7303184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020515812A 2017-05-24 2018-05-24 凍結保存細胞製剤および細胞再生方法 Active JP7303184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710375424.XA CN108925548A (zh) 2017-05-24 2017-05-24 一种冻存细胞制剂及细胞复苏方式
CN201710375424.X 2017-05-24
PCT/CN2018/088246 WO2018214943A1 (zh) 2017-05-24 2018-05-24 一种冻存细胞制剂及细胞复苏方式

Publications (3)

Publication Number Publication Date
JP2020520680A JP2020520680A (ja) 2020-07-16
JP2020520680A5 JP2020520680A5 (enExample) 2021-07-26
JP7303184B2 true JP7303184B2 (ja) 2023-07-04

Family

ID=64396262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515812A Active JP7303184B2 (ja) 2017-05-24 2018-05-24 凍結保存細胞製剤および細胞再生方法

Country Status (8)

Country Link
US (1) US20200170242A1 (enExample)
EP (1) EP3632207A4 (enExample)
JP (1) JP7303184B2 (enExample)
KR (1) KR102350423B1 (enExample)
CN (1) CN108925548A (enExample)
AU (1) AU2018272688B2 (enExample)
NZ (1) NZ759568A (enExample)
WO (1) WO2018214943A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
AU2021245671A1 (en) * 2020-03-31 2022-10-20 Cell Exosome Therapeutics Inc. Cell preservation method
AU2021324669A1 (en) * 2020-08-10 2023-02-23 Angiocrine Bioscience, Inc. Cryopreserved endothelial cell compositions
TW202245811A (zh) * 2021-02-03 2022-12-01 美商異基因治療有限公司 用於ｃａｒ ｔ細胞藥物產品的調配物與製程
US20220354108A1 (en) * 2021-05-04 2022-11-10 Tissue Testing Technologies Llc Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol
CN113994951A (zh) * 2021-11-17 2022-02-01 晋文娟 一种cik细胞冻存液及冻存方法
CN114097771B (zh) * 2021-12-15 2022-10-14 珠海贝索细胞科学技术有限公司 一种细胞保存液及其应用和细胞保存方法
CN115136955A (zh) * 2022-08-03 2022-10-04 深圳宾德生物技术有限公司 细胞冻存液及其制备方法和应用
CN116058363B (zh) * 2023-01-13 2025-10-28 杭州中赢生物医疗科技有限公司 一种增加nk细胞冻存复苏后活性的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005013223A (ja) 2003-06-03 2005-01-20 Lymphotec:Kk 造血幹細胞移植後の生着安定組成物、該組成物を得るためのキット、造血幹細胞移植後の生着安定方法、ヒトモノクローナル抗体あるいはヒトポリクローナル抗体およびそれらの製法、ヒトモノクローナル抗体をコードする遺伝子および該遺伝子が導入された形質転換体
WO2016007506A1 (en) 2014-07-07 2016-01-14 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
JP2017501740A (ja) 2013-11-04 2017-01-19 アイソポジェン ピーティーワイ リミテッド 細胞培養方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713245B2 (en) * 1998-07-06 2004-03-30 Diacrin, Inc. Methods for storing neural cells such that they are suitable for transplantation
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7270946B2 (en) * 2002-10-04 2007-09-18 Organ Recovery Systems, Inc. Method for treatment of cellular materials with sugars prior to preservation
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN102119936B (zh) * 2011-03-07 2012-12-12 李荣旗 制备利用人羊膜间充质细胞治疗缺血性脑损伤注射液的方法及其注射液
CN103461322B (zh) * 2012-06-07 2016-08-03 西比曼生物科技（上海）有限公司 用于冻存复苏后的细胞的保存液
CN102907416B (zh) * 2012-08-01 2016-08-03 西比曼生物科技（上海）有限公司 一种可维持细胞活性的组织冻存液
CN102792947B (zh) * 2012-09-03 2014-03-26 四川新生命干细胞科技股份有限公司 一种间充质干细胞冻存液及注射液
CN102908364A (zh) * 2012-11-14 2013-02-06 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗儿童扩张型心肌病药物中的应用
CN104430301A (zh) * 2014-11-18 2015-03-25 成都康华生物制品有限公司 一种提高人二倍体细胞存活率的方法
US20180116956A1 (en) * 2015-04-02 2018-05-03 Stegi-Ra Trust Composition for use in treating celiac disease
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
CN104857022A (zh) * 2015-05-21 2015-08-26 北京青藤谷禧干细胞科技研究院有限公司 一种间充质干细胞注射液、制备方法及其应用
CN105394026B (zh) * 2015-10-31 2017-09-29 北京军科联合干细胞生物科技有限公司 一种造血干细胞冻存新方法
CN105325402A (zh) * 2015-11-13 2016-02-17 黄林海 一种用于玻璃化冻存骨髓间充质干细胞的冻存保护剂
CN105477017A (zh) * 2015-12-03 2016-04-13 深圳爱生再生医学科技有限公司 治疗糖尿病足的混合干细胞制剂及其制备方法
CN105660606B (zh) * 2016-03-10 2018-04-03 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CN106665560B (zh) * 2017-01-16 2021-02-05 哈尔滨医科大学 一种直接静脉回输的免疫细胞冻存液及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005013223A (ja) 2003-06-03 2005-01-20 Lymphotec:Kk 造血幹細胞移植後の生着安定組成物、該組成物を得るためのキット、造血幹細胞移植後の生着安定方法、ヒトモノクローナル抗体あるいはヒトポリクローナル抗体およびそれらの製法、ヒトモノクローナル抗体をコードする遺伝子および該遺伝子が導入された形質転換体
JP2017501740A (ja) 2013-11-04 2017-01-19 アイソポジェン ピーティーワイ リミテッド 細胞培養方法
WO2016007506A1 (en) 2014-07-07 2016-01-14 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use

Also Published As

Publication number Publication date
KR102350423B1 (ko) 2022-01-11
WO2018214943A1 (zh) 2018-11-29
US20200170242A1 (en) 2020-06-04
EP3632207A4 (en) 2021-03-10
KR20200073171A (ko) 2020-06-23
AU2018272688B2 (en) 2021-05-27
JP2020520680A (ja) 2020-07-16
NZ759568A (en) 2023-01-27
AU2018272688A1 (en) 2019-12-19
EP3632207A1 (en) 2020-04-08
CN108925548A (zh) 2018-12-04

Similar Documents

Publication Publication Date Title
JP7303184B2 (ja) 凍結保存細胞製剤および細胞再生方法
JP6029468B2 (ja) 心臓病治療用医薬組成物
JP5394932B2 (ja) ヒト間葉系幹細胞含有医薬組成物
Musialek et al. Original paper Myocardial regeneration strategy using Wharton’s jelly mesenchymal stem cells as an off-the-shelf ‘unlimited’therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study
Hanna et al. Preservation of stem cells
CN105994254A (zh) 一种dc细胞的冻存液及冻存方法
US20230180740A1 (en) Method for administering umbilical cord blood or peripheral blood
CN105941389A (zh) 一种无动物源血清的细胞冻存液
Cantero Peral et al. Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system
CN115039763A (zh) 一种免疫细胞冻存液
Hoogendoorn et al. Formulation of cell-based medicinal products: a question of life or death?
CN109315386A (zh) 一种可用于造血干细胞或淋巴细胞的冻存液及冻存方法
JP5379340B2 (ja) ヒト自己前駆幹細胞を培養する培地とその応用
JP2008528034A (ja) 直ぐに利用可能な臍帯血から誘導される細胞物質、及びその組成物の提供方法
WO2022001025A1 (zh) 干细胞冻存保护剂、制备方法及应用
CN114403127A (zh) 一种间充质干细胞冷藏保护液及保存方法
Flahaut et al. Reassessing long-term cryopreservation strategies for improved quality, safety, and clinical use of allogeneic dermal progenitor cells
WO2021213446A1 (zh) 生物样品低温储存
CN112450206A (zh) 一种直接静脉使用的非程序细胞冻存液
CN207121593U (zh) 一种冻存细胞试剂盒
HK40017286A (en) Cell cryopreservation formulation and cell recovery method
JP2013252126A (ja) デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
NL2034495B1 (en) Stem cell cryopreservation protective agent, preparation method, and application thereof
El-Hashash Stem cell innovation in cardiovascular disease, repair, and regeneration: general conclusion, challenges and prospective
Veronesi et al. cGMP-compliant transportation conditions for a prompt therapeutic use of marrow mesenchymal stromal/stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200318

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210119

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230329

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230622

R150 Certificate of patent or registration of utility model

Ref document number: 7303184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350